DENVER, Feb. 07, 2017 -- Air Methods Corporation (Nasdaq:AIRM), the global leader in air medical transportation, today reported preliminary patient transport and tourism passenger data for the month of January 2017.
| Air Medical | Jan-17 | Jan-16 | YOY Change (%) | |||
| Transports | 4,919 | 5,219 | -5.7 | % | ||
| Transports + Weather Cancellations | 8,347 | 7,564 | 10.4 | % | ||
| Same-Base Transports (SBTs) | 4,237 | 4,779 | -11.3 | % | ||
| SBT + Weather Cancellations | 7,330 | 7,042 | 4.1 | % | ||
| Tourism | Jan-17 | Jan-16 | YOY Change (%) | |||
| Passengers | 34,211 | 29,591 | 15.6 | % | ||
Aaron Todd, CEO of Air Methods, stated, “Patient transports were impacted negatively by weather in January. As a percent of requests, weather cancellations represented 29.1% of requests, the highest for any month over the past six years. On an encouraging note, same-base requests grew slightly (0.1%) after declining in the prior eight months.”
About Air Methods Corporation
Air Methods Corporation (www.airmethods.com) is the global leader in air medical transportation. The Air Medical Services Division is the largest provider of air medical transport services in the United States. The United Rotorcraft Division specializes in the design and manufacture of aeromedical and aerospace technology. The Tourism Division is comprised of Sundance Helicopters, Inc. and Blue Hawaiian Helicopters, which provide helicopter tours and charter flights in the Las Vegas/Grand Canyon region and Hawaii, respectively. Air Methods’ fleet of owned, leased or maintained aircraft features approximately 500 helicopters and fixed wing aircraft.
Forward Looking Statements: Forward-looking statements in this news release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements in this press release that are “forward-looking statements”, including statements we make with regard to preliminary results of (i) total transports, (ii) same-base transports, (iii) weather cancellations, (iv) tourism passengers, and (v) same-base requests for January 2017 are based on current expectations and assumptions that are subject to risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors, including but not limited to the Company’s completion of its first quarter closing and review procedures and other matters set forth in the Company's filings with the SEC. The Company is under no obligation (and expressly disclaims any obligation) to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACTS: Peter P. Csapo, Chief Financial Officer, ([email protected]). Please contact Christina Brodsly Ward at ([email protected]) to be included on the Company’s e-mail distribution list.


Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock
Instagram Outage Disrupts Thousands of U.S. Users
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 



